Tag Archives: policy
By Ben Comer | Published: February 5, 2013
Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access to individual patients in their hour of need.
By William Looney | Published: January 30, 2013
Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement Monday, February 4, is World Cancer Day. Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the […]
By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
By Guest Blogger | Published: May 1, 2012
By Tom Norton As the US Department of Health and Human Services (HHS) circles around the elements of health care that will actually be included in our new “Essential Health Benefits” (EHB), one aspect of the EHB offering has caused a tremendous stir among dozens of health groups. Their collective concern is focused on the […]
By Ben Comer | Published: March 30, 2012
This June, Californians will be asked whether cigarette smokers should subsidize research to treat diseases related to smoking cigarettes. California’s Proposition 29, if passed, would levy an additional tax of $1 on every pack of smokes sold in the state beginning in October 2012. The tax would generate an estimated $615 million in 2012/2013, and […]